Antithrombotic management in atrial fibrillation;Prise en charge antithrombotique dans la fibrillation atriale

Revue du Praticien

Volumn 63, Issue 2, 2013, Pages 199-206

  Fauchier, Laurent ^a   Taillandier, Sophie ^a   Clementy, Nicolas ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; REVIEW; RISK FACTOR;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; CHOICE BEHAVIOR; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; RISK FACTORS;

EID: 84875019072     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
2. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-72.
4. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100.
5. 2-VASc score = 0 in a community-based cohort study. J Cardiovasc Electrophysiol 2012;23:708-13.
6. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
7. Connolly SJ, Pogue J, Hart RG, et al. Effect of Clopidogrel added to aspinn in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
8. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-49.
9. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. (Pubitemid 47212371)
10. Connolly SJ, Ezekowitz MD, Yusuf S, et al RE-LY Steering Committee and Investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
11. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6.
12. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
13. Granger CB, Alexander JH, McMurray JJ, et al ARISTOTLE Committees and Investigators. Apixaban vs. warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.